Clinical Trials · NCT01767090
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Astellas Pharma Europe B.V.
- Enrollment
- 912
- Start date
- Dec 2012
- Locations
- 85 sites, 9 countries
- Primary endpoint
- Change from baseline to the end of 12 weeks treatment of pain score for overall pelvic pain